Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 2/20 | 0.37 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CEL | P19835 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1482399 | 1.00 | SIGMAR1 (0.56) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL5171202 | 1.00 | SIGMAR1 (0.56) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL94877 | 1.00 | SIGMAR1 (0.56) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL25313409 | 1.00 | SIGMAR1 (0.56) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL3027416 | 1.00 | SIGMAR1 (0.56) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL25313563 | 1.00 | SIGMAR1 (0.56) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL65834 | 0.97 | SIGMAR1 (0.60) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL646878 | 0.97 | SIGMAR1 (0.60) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL8499356 | 0.97 | SIGMAR1 (0.60) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL2290342 | 0.97 | SIGMAR1 (0.60) | SIGMAR1CYP1A2EPHX1KDM5APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 738 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3688124-B1 | ESTER COMPOUNDS, LUBRICATING OIL COMPOSITIONS CONTAINING SAME AND PROCESSES FOR MAKING SAME | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2023-10-25 | — | — | EP | claimed |
| CN-116848094-A | Tertiary amine lipid compounds and uses thereof | 华南理工大学 | 2023-10-03 | — | — | CN | claimed |
| US-10955421-B2 | Detection of membrane proteins | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-03-23 | — | — | US | claimed |
| WO-2020239103-A1 | BTK INHIBITOR RING DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | 四川海思科制药有限公司 | 2020-12-03 | — | — | WO | claimed |
| EP-3688124-A1 | ESTER COMPOUNDS, LUBRICATING OIL COMPOSITIONS CONTAINING SAME AND PROCESSES FOR MAKING SAME | ExxonMobil Chemical Patents Inc. (US) | 2020-08-05 | — | — | EP | claimed |
| US-20200240997-A1 | DETECTION OF MEMBRANE PROTEINS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2020-07-30 | — | — | US | claimed |
| US-10711216-B2 | Ester compounds, lubricating oil compositions containing same and processes for making same | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2020-07-14 | — | — | US | claimed |
| CN-111386331-A | Ester compound, lubricating oil composition containing same, and method for producing same | 埃克森美孚化学专利公司 | 2020-07-07 | — | — | CN | claimed |
| CN-110002483-A | The recovery method of alchlor in a kind of Friedel-Crafts reaction | 山东盛华新材料科技股份有限公司 | 2019-07-12 | — | — | CN | claimed |
| EP-2504288-B1 | OPTICAL FIBER WITH DOUBLE COATING | PRYSMIAN SPA (IT) | 2019-04-17 | — | — | EP | claimed |
| EP-0651739-A1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS. | BRITISH BIOTECH PHARM (GB) | 1995-05-10 | — | — | EP | claimed |
| EP-0651738-A1 | NATURAL AMINO ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-05-10 | — | — | EP | claimed |
| WO-1994024140-A1 | HYDROXAMIC ACID DERIVATIVES | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1994-10-27 | — | — | WO | claimed |
| US-5358961-A | Hypotensive agents | JIN RO LIMITED (KR) | 1994-10-25 | — | — | US | claimed |
| WO-1994002446-A1 | NATURAL AMINO ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1994-02-03 | — | — | WO | claimed |
| WO-1994002447-A1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1994-02-03 | — | — | WO | claimed |
| WO-1993011136-A1 | NEW PYRROLIDINE DERIVATIVES | JIN RO LIMITED (KR) | 1993-06-10 | — | — | WO | claimed |
| EP-0108570-B1 | DISAZO DYESTUFFS FOR CELLULOSE-CONTAINING FIBRES AND PROCESS FOR PREPARING THE DYESTUFF | MITSUBISHI KASEI CORPORATION (JP) | 1986-10-29 | — | — | EP | claimed |
| US-4548818-A | Composition and methods for the treatment of chronic obstructive airway disease and cardiac disease using 3-alkylxanthines | AKTEBOLAGET DRACO, A COMPANY OF SWEDEN (SE) | 1985-10-22 | — | — | US | claimed |
| EP-0108570-A2 | Disazo dyestuffs for cellulose-containing fibres and process for preparing the dyestuff | MITSUBISHI KASEI CORPORATION (JP) | 1984-05-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200240997-A1 | DETECTION OF MEMBRANE PROTEINS | CETP, VAPA, PCTP | SIGMAR1 1681/4885CYP1A2 4746/4885EPHX1 2386/4885 |
| US-10711216-B2 | Ester compounds, lubricating oil compositions containing same and processes for making same | ELOVL1, NOTUM, ELOVL5 | SIGMAR1 1098/4885CYP1A2 913/4885EPHX1 384/4885 |
| US-10955421-B2 | Detection of membrane proteins | CETP, VAPA, PCTP | SIGMAR1 1681/4885CYP1A2 4746/4885EPHX1 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.